Colonic delivery of docosahexaenoic acid improves impaired glucose tolerance via GLP-1 secretion and suppresses pancreatic islet hyperplasia in diabetic KK-Ay mice

International Journal of Pharmaceutics

Volumn 450, Issue 1-2, 2013, Pages 63-69

  Shida, Takayuki ^a   Kamei, Noriyasu ^b   Takeda Morishita, Mariko ^b   Isowa, Koichi ^c   Takayama, Kozo ^d  

^a ONO PHARMACEUTICAL CO   (Japan)

^b KOBE GAKUIN UNIVERSITY   (Japan)

^c Intelligence and Technology Lab (I Tech Lab)   (Japan)

^d HOSHI UNIVERSITY   (Japan)

Author keywords

Colonic delivery; Docosahexaenoic acid; Glucose tolerance; Pancreatic islet hyperplasia; Type 2 diabetes mellitus

Indexed keywords

DOCOSAHEXAENOIC ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL GROWTH; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HORMONE RELEASE; IMMUNOHISTOCHEMISTRY; IMPAIRED GLUCOSE TOLERANCE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL HYPERPLASIA; PRIORITY JOURNAL;

ANIMALS; BLOOD GLUCOSE; COLON; DIABETES MELLITUS, TYPE 2; DOCOSAHEXAENOIC ACIDS; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; HYPERPLASIA; HYPOGLYCEMIC AGENTS; ISLETS OF LANGERHANS; MALE; MICE; MICE, TRANSGENIC;

EID: 84877590178     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.04.029     Document Type: Article

References (18)

1. T. Adachi, T. Tanaka, K. Takemoto, T.A. Koshimizu, A. Hirasawa, and G. Tsujimoto Free fatty acids administered into the colon promote the secretion of glucagon-like peptide-1 and insulin Biochem. Biophys. Res. Commun. 340 2006 332 337
2. S.L. Conarello, Z. Li, J. Ronan, R.S. Roy, L. Zhu, G. Jiang, F. Liu, J. Woods, E. Zycband, D.E. Moller, N.A. Thornberry, and B.B. Zhang Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance Proc. Natl. Acad. Sci. USA 100 2003 6825 6830
3. D.J. Drucker Minireview: the glucagon-like peptide Endocrinology 142 2001 521 527
4. L. Farilla, H. Hongxiang, C. Bertolotto, E. Kang, A. Bulotta, U.D.I. Mario, and R. Perfetti Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats Endocrinology 143 2002 4397 4408
5. K. Fillipsson, M. Kvist-Reimer, and B. Ahrén The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function Diabetes 50 2001 1959 1969
6. A. Hirasawa, K. Tsumaya, T. Awaji, S. Katsuma, T. Adachi, M. Yamada, and Y. Sugimoto Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120 Nat. Med. 11 2005 90 94
7. T. Itoh, and K. Yamamoto Peroxisome proliferator activated receptor γ and oxidized docosahexaenoic acids as new class of ligand Naunyn. Schmiedebergs Arch. Pharmacol. 377 2008 541 547
8. T.J. Kieffer, C.H.S. McIntosh, and R.A. Pederson Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 136 1995 3585 3596
9. K.A. Klinteberg, S. Karlsson, and B. Ahrén Signaling mechanisms underlying the insulinotropic effect of pituitary adenylate cyclase-activating polypeptide in HIT-T15 cells Endocrinology 137 1996 2791 2798
10. Y. Li, T. Hansotia, B. Yusta, F. Ris, P.A. Halban, and D.J. Drucker Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis J. Biol. Chem. 278 2003 471 478
11. M. Morishita, T. Tanaka, T. Shida, and K. Takayama Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion J. Control. Release 132 2008 99 104
12. A. Pick, J. Clark, C. Kubstrup, M. Levisetti, W. Pugh, S. Bonner-Weir, and K.S. Polonsky Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat Diabetes 47 1998 358 364
13. J.N. Roberge, and P.L. Brubaker Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients Endocrinology 128 1991 3169 3174
14. R. Scott, M. Wu, M. Sanchez, and P. Stein Efficiency and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes Int. J. Clin. Pract. 61 2007 171 180
15. T. Tanaka, T. Yano, T. Adachi, T.A. Koshimizu, A. Hirasawa, and G. Tsujimoto Cloning and characterization of the rat free fatty acid receptor GPR120: in vivo effect of the natural ligand on GLP-1 secretion and proliferation of pancreatic β cells Naunyn Schmiedebergs Arch Pharmacol. 377 2008 515 522
16. S. Tomimoto, H. Hashimoto, N. Shintani, K. Yamamoto, Y. Kawabata, K.I. Hamagami, and K. Yamagata Overexpression of pituitary adenylate cyclase-activating polypeptide in islets inhibits hyperinsulinemia and islet hyperplasia in Agouti Yellow mice J. Pharmacol. Exp. Ther. 309 2004 796 803
17. D. Vaudry, B.J. Gonzalez, M. Basille, L. Yon, A. Fournier, and H. Vaudry Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions Pharmacol. Rev. 52 2000 269 324
18. K. Yamamoto, H. Hashimoto, S. Tomimoto, N. Shintani, J.I. Miyazaki, F. Tashiro, and H. Aihara Overexpression of PACAP in transgenic mouse pancreatic β-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes Diabetes 52 2003 1155 1162